Serum Institute of India receives purchase order from Govt. of India
The Drug Controller General of India (DCGI) had approved the emergency use of both Serum Institute of India (SII)'s Covishield and Bharat Biotech’s Covaxin for emergency use against COVID-19 in India. An expert panel of Central Drugs Standard Control Organization (CDSCO) recommended them for emergency use.
Also Read | Air India flight with all-women cockpit crew successfully lands
Serum Institute of India (SII) officials stated, "The vaccine would be available at the price of Rs 200 per dose."
https://twitter.com/ANI/status/1348600017573933070?s=20
According to the sources, Serum Institute of India (SII) produced Covishield dispatch likely to be early morning tomorrow.
Also Read | SII announces COVID vaccine cost for Govt. and Public
According to the reports, India will not allow the export of the Oxford University-AstraZeneca coronavirus vaccine for several months, Serum Institute of India has been contracted to make 1 billion doses of the vaccine for developing nations.
Adar Poonawalla, chief executive of Serum Institute of India had earlier said, “The Oxford vaccine will be sold for Rs 200 per dose to the government while it will be available for Rs 1,000 for the general public.”
Adding that Serum Institute has the capacity to manufacture 5,000 doses of vaccine per minute and already 40 to 50 million doses of the vaccine is ready for dispatch.
Serum Institute is also negotiating bilateral agreements with individual countries including Bangladesh, Saudi Arabia and Morocco. “So that at least the most vulnerable in the states of our country or in other parts of other countries are taken care off,” he mentioned.
-PTC News
